Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
U1 small nuclear RNA variant 31 (RNVU1-31) is a variant of the U1 small nuclear RNA (snRNA), a core component of the U1 small nuclear ribonucleoprotein (snRNP) complex[7][8]. U1 snRNA and its variants are central non-coding RNAs that function as part of the spliceosome, where they are involved in the recognition and binding of the 5′ splice site during pre-mRNA splicing in eukaryotic cells[1][3][6]. This process is essential for the accurate removal of introns from pre-mRNA transcripts. Alterations or mutations in U1 snRNA can disrupt normal splicing, leading to aberrant mRNA transcripts, and have been implicated in cryptic splicing events in certain tumors[2]. RNVU1-31 itself is not known to be a direct therapeutic target or receptor for any drugs and, as an snRNA, does not possess enzymatic or receptor activity. It is primarily classified as a non-coding RNA with structural and regulatory roles in RNA processing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U1 small nuclear RNA variant 31 (RNVU1-31).